Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... cells, announced today that it will be,participating in the ... 10, 2008., The Company,s presentation by Dr. William ... Standard Time (11:50 am, Pacific Standard,Time), and will be ...
... cubes and spheres move aside. Tiny gold stars, smaller ... for new approaches to medical diagnoses or testing for environmental ... wide spectrum of sciences, a new study by Duke University ... stars may shine above all the rest for certain applications. ...
... Upon a Proven Class of Drugs With Greater Tumor ... (Nasdaq: ONXX ) today announced that it has,in-licensed ... Limited based in the United Kingdom. Under the terms ... BGC 945 and all of its,related patents. Onyx will ...
Cached Biology Technology:ThermoGenesis Presentation at Rodman & Renshaw Conference 2Gold nanostar shape of the future 2Gold nanostar shape of the future 3Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 2Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 3
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
(Date:8/26/2014)... of Warwick have provided the first evidence that ... linked to early signs of dementia. , Published ... that the absence of the protein MK2/3 promotes ... nervous system. These changes were shown to have ... including restricted learning and memory formation capabilities. , ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2Yale journal explores advances in sustainable manufacturing 2
... 2011 -- Research presented today at the 31st Annual meeting ... Meeting has found that three proteins known as XIAP, BID, ... progesterone treatments in the prevention of preterm labor. They ... The proteins prevent preterm birth by hindering ...
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... the 4th Congress of the International Society for Hemodialysis ... "The Treatment of HCV with Affinity Plasmapheresis." The conference ...
... today at the 31st Annual meeting of the Society for ... three proteins known as XIAP, BID, and Bcl-2 are responsible ... prevention of preterm labor. They may also play an ... proteins prevent preterm birth by hindering apoptosis the normal, ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 3Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 4Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 5New research helps explain how progesterone preventspreterm birth 2
... The new D-LUX Detection Platform combines ... provide the most sensitive, specific, and ... Invitrogens D-LUX Detection Platform offers exceptional ... to TaqMan probes, high signal/background ratio, ...
...
Request Info...
... Blood is aseptically collected via cardiac puncture ... Zealand White, mixed sex). It is then centrifuged ... pooled, sterile filtered and bottled at 4C then ... IF YOU HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU ...
Biology Products: